Abivax Shares Drop 3.6% and Plunge to the Bottom of the SBF 120 as Short Selling Soars
The French biotech company falls during the session and sinks to the bottom of the broad Parisian index. The stock extends a decline that began several weeks ago, as short sellers have significantly increased their positions in the capital.
The Stock Dips Below Its Moving Averages and Ranks at the Bottom of the SBF 120
Abivax shares drop 3.6% to €83.10 during the session, while the SBF 120 barely gains 0.09%. The stock is among the largest declines in the broad index, trailing behind Pluxee and Edenred. The downturn is part of a fundamental bearish trend, with a loss of 13.1% over one month and 22.6% over three months, despite a still impressive annual performance of over 1,400%.
The price now moves below its three moving averages, with a gap of 10.7% below the MM20 (€93.02) and 13% below the MM200 (€95.48), indicating a break in the bullish momentum of recent months. The RSI at 44 remains neutral, with no sign of seller exhaustion, while the next identified support is at €63.10.
Short Positions Sharply Increase Amid Doubts Post-Phase 3
According to reviewed statements, four funds now hold a cumulative 5.54% of the capital sold short, up from 2.12% a month ago, marking a 3.42 point increase in thirty days. This rapid rise signals that some institutional investors are positioning against the stock or seeking to hedge an exposure, in a context where the market continues to digest the phase 3 results of obefazimod published in early June. As a reminder, on June 1st, 2026, both doses of the drug candidate achieved the primary endpoint of clinical remission in ulcerative colitis, but several safety signals caused a 31% drop in the stock the following day. The company, listed on both Euronext Paris and the Nasdaq as ADS since October 2023, remains closely monitored by traders as the price approaches the €80 zone.
